INM

Business Context and Reporting Period

Company: InMed Pharmaceuticals Inc. (INM)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2024
Business Overview: InMed is a clinical-stage pharmaceutical company developing proprietary small molecule drug candidates targeting the endocannabinoid system (CB1 and CB2 receptors) for diseases with high unmet medical needs. The company operates two segments: InMed Pharma (pharmaceutical R&D) and BayMedica Commercial (B2B sales of bulk rare cannabinoids for the health and wellness sector).
Key Pipeline Assets:

• INM-901: Alzheimer's disease (Preclinical/IND-enabling).
• INM-089: Dry Age-related Macular Degeneration (Preclinical).
• INM-755: Epidermolysis Bullosa (Phase 2 completed; seeking partners).

Key Financial Metrics

Note: Revenue is derived entirely from the BayMedica segment. The InMed Pharma segment generated no revenue.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 11% to $4.6 million, driven by expanded marketing and demand for rare cannabinoids (CBC, CBDV, THCV, CBT) in the health and wellness sector.
• Gross Margin Compression: Gross profit decreased 22% to $1.1 million. Cost of sales rose 28% due to increased personnel costs for the cost of goods function and higher sales volume.
• Operating Expenses: Total operating expenses decreased 5% to $9.3 million. General and administrative expenses dropped 10% due to lower office, investor relations, and personnel costs. R&D expenses remained relatively flat (up 1%).
• Liquidity: Cash and cash equivalents decreased by approximately $2.3 million year-over-year, primarily due to operating losses and financing activities net of issuance costs.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Guidance

Management estimates current cash resources ($6.6 million) are sufficient to fund operations through the end of the fourth quarter of calendar 2024 (Q2 FY2025). The company expects to incur substantial operating losses in the foreseeable future and will require additional capital to advance clinical trials and commercialization efforts.

Material Risks and Contingencies

• Going Concern: The company has incurred recurring losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern within one year of the report issuance. The auditor included an explanatory paragraph regarding this uncertainty.
• Nasdaq Delisting: On September 17, 2024, the company received notice of delisting from Nasdaq for failing to maintain the minimum bid price ($1.00) requirement. An appeal hearing is scheduled for October 31, 2024. Delisting could severely impact liquidity and access to capital.
• Internal Controls: A material weakness in internal control over financial reporting identified in FY2023 (related to segregation of duties) has been remediated as of June 30, 2024.
• Legal Proceedings: BayMedica is involved in a dispute regarding a Patent License Agreement with a third-party licensor. The licensor has alleged breach and asserted rights to monies due; BayMedica disputes these claims. No lawsuit has been filed as of the report date.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $6.6 million cash balance to fund operations beyond Q4 2024, given the substantial doubt on going concern status.
• Nasdaq Status: Monitor the outcome of the Nasdaq appeal hearing scheduled for October 31, 2024, and the potential impact on stock liquidity and trading venue.
• Financing Needs: Assess the company's ability to raise additional capital through equity offerings (including the ATM program) or strategic partnerships to fund clinical trials for INM-901 and INM-089.
• BayMedica Margins: Review the trend in BayMedica's gross margins, which declined despite revenue growth, to understand cost structure sustainability.
• Legal Dispute: Track the status of the Patent License Agreement dispute with BayMedica's licensor for potential financial exposure.